IMAB Overview

Corporate Rebranding: I-Mab has officially changed its name to NovaBridge Biosciences, reflecting its strategic transformation into a global biotech platform aimed at enhancing access to innovative medicines. The new name and ticker symbol "NBP" will be effective on Nasdaq starting October 30, 2025.

Strategic Growth Plans: The company plans to pursue a dual listing on both Nasdaq and the Hong Kong Stock Exchange (HKEX) to broaden its investor base and enhance trading liquidity, while also forming a new subsidiary, Visara, to focus on developing specialized therapeutics.

Pipeline Development: NovaBridge's key assets include givastomig, a bispecific antibody for gastric cancer, and VIS-101, a bifunctional biologic targeting retinal diseases. Both are advancing through clinical trials, with significant milestones expected in the near future.

Business Model: The company employs a "hub-and-spoke" model to manage risk and create value through specialized subsidiaries, allowing for focused development of high-potential drug candidates in collaboration with leading innovators.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing trading strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving I-Mab and its executives, urging affected investors to reach out for assistance.

New Business Model: On October 16, 2025, I-Mab announced a shift to a new business model focused on partnerships and specialized subsidiary companies, alongside plans for a dual listing on NASDAQ and the Hong Kong Stock Exchange.

Stock Price Reaction: Following the announcement of its new business strategy, I-Mab's American Depositary Receipt (ADR) price dropped by 12.04%, closing at $5.77 on October 17, 2025.

Pomerantz LLP Background: Pomerantz LLP, a leading firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved significant recoveries for class members.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify stocks with strong momentum indicators.

I-Mab Sponsored ADR Performance: I-Mab (IMAB) has a Momentum Style Score of A and a Zacks Rank of #2 (Buy), with significant price increases of 124.54% over the past quarter and 270.23% over the last year, outperforming the S&P 500.

Earnings Estimates and Trading Volume: Recent earnings estimates for IMAB have improved, with upward revisions indicating positive momentum. Additionally, the stock's average trading volume suggests strong investor interest.

Investment Recommendations: Experts recommend keeping I-Mab on investors' short lists for potential near-term gains, alongside other top stock picks from Zacks Investment Research.

Wolfspeed's Reorganization: Wolfspeed, Inc. announced a court-approved reorganization plan that will reduce its debt by 70% and interest payments by 60%, leading to a 50.9% increase in its stock price during pre-market trading.

Other Notable Stock Movements: Several companies saw significant pre-market trading gains, including Sunrise New Energy Co. (up 97%) and Vivakor, Inc. (up 67%), while others like Epsium Enterprise Limited and Artelo Biosciences, Inc. experienced notable declines.